{
    "clinical_study": {
        "@rank": "13272", 
        "arm_group": {
            "arm_group_label": "Dendritic cell application", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The main aim of this trial is to assess the response rate, the feasibility and toxicity of\n      the treatment with antigen loaded Dendritic Cell Vaccination in Prostate Cancer patients.\n      Furthermore we want to investigate biological responses by measuring markers of in-vivo and\n      ex-vivo immunomodulation."
        }, 
        "brief_title": "Phase I/II Study of Vaccination With Antigen Loaded Dendritic Cells (DCs) in Hormone-Refractory Prostate Cancer", 
        "completion_date": {
            "#text": "October 2011", 
            "@type": "Actual"
        }, 
        "condition": "Cancer of the Prostate", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  histologically or cytologically proven prostatic carcinoma\n\n          -  proven hormonal resistance: tumor progression after orchiectomy or during treatment\n             with hormonal agents. Patients treated with antiandrogens, such as flutamide\n             (Flucinom) or bicalutamide (Casodex), should have been discontinued the drug 6 weeks\n             prior to the trial entry followed by no tumor response within this 6 weeks\n\n          -  not amenable to curative therapy\n\n          -  patients with measurable and non-measurable disease may be included. Bone lesions\n             only are considered to be non-measurable\n\n          -  two consecutive increases of prostate-specific antigen (PSA) should be documented\n             over a previous reference value (N\u00b01). The first increase in PSA (N\u00b02) should occur a\n             minimum of one week from the reference value and be confirmed (N\u00b03). If this value is\n             less than the previous value, the patient is still eligible if the next PSA(N\u00b04) is\n             found to be higher than the second PSA. Serum levels of prostate-specific antigen\n             must be at least 10 microg/l\n\n          -  Previous radiotherapy is allowed if it has been stopped 4 weeks or more before the\n             trial treatment and did not involve lesions used to evaluate activity of the trial\n             drugs\n\n          -  one previous chemotherapy (including Estracyt) is allowed, but the chemotherapy\n             should have been stopped at least 6 weeks before study entry\n\n          -  age >18 years\n\n          -  performance status 0,1,2 (ECOG, Appendix I)\n\n          -  no concurrent therapy with steroids\n\n          -  no uncontrolled infections\n\n          -  live expectancy more than 3 months\n\n          -  Human leukocyte antigen (HLA)-Type has to be HLA*A201\n\n          -  neutrophile count >1500/microl and thrombocytes >100 000/microl\n\n          -  creatinine <1.5 of upper normal level\n\n          -  adequate liver function with bilirubin <2 of upper normal level, alanine\n             aminotransferase (ALAT) and aspartate transamionase (ASAT) < 3 x upper normal level\n\n          -  absence of any psychological, familial, sociological or geographical condition\n             potentially hampering compliance with the study protocol and follow-up schedule;\n             those conditions should be discussed with the patient before registration in the\n             trial\n\n          -  before patient registration/randomization, informed consent must be given according\n             to good clinical practice (GCP), and national/local regulations\n\n        Exclusion Criteria:\n\n          -  serious concomitant disease (cardiac, pulmonary and others)\n\n          -  brain metastasis\n\n          -  previous splenectomy or radiotherapy to the spleen\n\n          -  concurrent therapy with immunosuppressive drugs\n\n          -  chronic immunosuppression (includes transplantation or HIV-infection) HIV, hepatitis\n             B virus (HBV), hepatitis C virus (HCV) (test required) or any other severe\n             uncontrolled infection other neoplastic diseases except: curatively treated basal\n             cell or squamous cell carcinoma of the skin or relapse free for more than 5 years\n             after curative treatment of a neoplasm\n\n          -  treatment with other investigational drugs during the last month\n\n          -  severe autoimmune disease\n\n          -  chemotherapy, radiotherapy or immunotherapy less than 6 weeks before study entry\n\n          -  Ejection fraction (measured by echocardiography) < 40%"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01897207", 
            "org_study_id": "SG226_02"
        }, 
        "intervention": {
            "arm_group_label": "Dendritic cell application", 
            "description": "S.C. injection of peptide pulsed autologous dendritic cells", 
            "intervention_name": "Dendritic cell application", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "prostate cancer", 
            "dendritic cells", 
            "vaccination"
        ], 
        "lastchanged_date": "August 19, 2013", 
        "number_of_arms": "1", 
        "official_title": "Phase I/II Study of Vaccination With Antigen Loaded Dendritic Cells (DCs) in Hormone-Refractory Prostate Cancer", 
        "overall_official": {
            "affiliation": "Department of Medical Oncology, Cantonal Hospital St. Gallen, Switzerland", 
            "last_name": "Thomas Cerny, Prof. Dr.", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Switzerland: Federal Office of Public Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "August 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "tolerability and toxicity and feasibility of this regimen", 
                "safety_issue": "Yes", 
                "time_frame": "directly after vaccination (within 24 h)"
            }, 
            {
                "description": "The given time frame reflects the minimum of PSA values. From Patients receiving more than 6 DC vaccination every 4 weeks PSA was determined until the end of DC vaccination (longest was one and a half year).", 
                "measure": "response rate or PSA response in non measurable disease", 
                "safety_issue": "No", 
                "time_frame": "Change from baseline in serum PSA at 6, 10 and 12 weeks"
            }, 
            {
                "description": "Peripheral blood mononuclear cells (PBMC) isolation and in-vitro restimulation. Measurement of antigen specific immune responses.", 
                "measure": "ex-vivo immunomodulation", 
                "safety_issue": "No", 
                "time_frame": "before vaccination, after 6, 10, 12, and up to 85 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01897207"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Cantonal Hospital of St. Gallen", 
            "investigator_full_name": "Prof. Dr. Silke Gillessen", 
            "investigator_title": "Prof. Dr.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Changes in pain intensity will be assessed by summarizing score items 9 and 19 of the European Organisation for Research and Treatment of Cancer (EORTC)quality of life questionnaire (QLQ-C30) quality. Additionally, analgesic consumption will be rated by a pain treatment score (PTS).", 
                "measure": "pain relief", 
                "safety_issue": "No", 
                "time_frame": "Change from baseline in pain relief at 2, 4, 6, 8, 10 and 12 weeks"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "From first date of treatment until dead"
            }
        ], 
        "source": "Cantonal Hospital of St. Gallen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cantonal Hospital of St. Gallen", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2002", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}